Pharmaceutical innovation and cancer survival : U.S. and international evidence by Lichtenberg, Frank R.
  
 
 
 
 
 
 
 
 
 
Pharmaceutical innovation and cancer survival: 
U.S. and international evidence 
 
 
Frank R. Lichtenberg* 
 
Columbia University 
 
and 
 
National Bureau of Economic Research 
 
 
 
 
 
 
 
 
 
 
* Graduate School of Business, Columbia University, 614 Uris Hall, 3022 Broadway, 
New York, NY 10027, frank.lichtenberg@columbia.edu, Phone: (212) 854-4408, Fax:   
(212) 316-219. 
 2
Pharmaceutical innovation and cancer survival: 
U.S. and international evidence 
 
Abstract 
 
The five-year relative survival rate from all malignant cancers increased from 
50.0% in 1975-1979 to 62.7% in 1995.  A variety of factors, including technological 
advances in diagnostic procedures that led to earlier detection and diagnosis, have 
contributed to this increase.  This paper’s main objective is to assess the contribution of 
pharmaceutical innovation to the increase in cancer survival rates.   
The percentage increase in the survival rate varied considerably across cancer 
sites.  I hypothesize that these differential rates of progress were partly attributable to 
different rates of pharmaceutical innovation for different types of cancer, and test this 
hypothesis within a “differences in differences” framework, by estimating models of 
cancer mortality rates using longitudinal, annual, cancer-site-level data based on records 
of 2.1 million people diagnosed with cancer during the period 1975-1995.  We control for 
fixed cancer site effects, fixed year effects, incidence, stage distribution of diagnosed 
patients, mean age at diagnosis, percent of patients having surgery, and percent of 
patients having radiation.   
Overall, the estimates indicate that cancers for which the stock of drugs increased 
more rapidly tended to have greater increases in survival rates.  The estimates imply that, 
ceteris paribus, the 1975-1995 increase in the stock of drugs increased the 1-year crude 
cancer survival rate from 69.4% to 76.1%, the 5-year rate from 45.5% to 51.3%, and the 
10-year rate from 34.2% to 38.1%.  The increase in the stock of drugs accounted for 
about 50-60% of the increase in age-adjusted survival rates in the first 6 years after 
diagnosis. 
I also estimate that the 1975-1995 increase in the lagged stock of drugs made the 
life expectancy of people diagnosed with cancer in 1995 just over a year greater than the 
life expectancy of people diagnosed with cancer in 1975.  This figure increased from 
about 9.6 to 10.6 years.  This is very similar to the estimate of the contribution of 
pharmaceutical innovation to longevity increase I obtained in an earlier study, although 
that study was based on a very different sample and methodology.  
Since the lifetime risk of being diagnosed with cancer is about 40%, the estimates 
imply that the 1975-1995 increase in the lagged stock of cancer drugs increased the life 
expectancy of the entire U.S. population by 0.4 years, and that new cancer drugs 
accounted for 10.7% of the overall increase in U.S. life expectancy at birth. 
The estimated cost to achieve the additional year of life per person diagnosed with 
cancer—below $3000—is well below recent estimates of the value of a statistical life-
year.  We are unable to measure quality-adjusted life-years (QALYS), but if new cancer 
drugs increased the quality of life as well as delayed death, the increase in QALYS is not 
necessarily less than the increase in life expectancy.   
I also investigate the effect of availability of new drugs on survival from 17 types 
of cancer in over 35 countries.  The model includes both fixed cancer-type effects and 
fixed country effects, which controls for all determinants of cancer survival that are 
invariant across cancer types within a given country, and that are invariant across 
countries for a given cancer type.  The estimates indicate that an increase in the number 
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of available drugs is associated with an increase in both the one-year and the five-year 
survival rate.   
The analysis indicates that variation in access to new drugs accounts for: (1) some 
of the variation over time in the relative survival rates of Americans with different types 
of cancer, and (2) some of the variation across countries in the relative survival rates in 
2000 of people with different types of cancer.  Access to new drugs explains a larger 
fraction of the time-series variation in longevity than it does of the international variation 
in longevity.  The evidence also supported the hypothesis that, ceteris paribus, the 
probability that a cancer drug has been launched in a country depends on the incidence of 
cancer cases eligible for treatment by that drug in that country.   
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In 1971, President Nixon declared “war on cancer”, and the National Cancer Act 
was enacted.1  Since that time, both government and industry have devoted enormous 
resources to fighting this war.  Today, it behooves us to ask, "Are we winning the war?" 
At first blush, the answer appears to be, “definitely not!”.  As Figure 1 
reveals, the age-adjusted U.S. mortality rate from all malignant cancers was 
essentially the same in 2000 as it was in 1969.  (It was 8% higher in 1991 than it was 
in 1969.)  During the same period, the age-adjusted mortality rate from all other 
causes of death declined by 38%.  Today, cancer is the leading cause of years of 
potential life lost before age 75.2  Some articles in both medical journals and the 
popular press have concluded that little progress has been made.  In an article entitled 
“Cancer undefeated” in the New England Journal of Medicine, Bailar and Gornik 
(1997) argued that “The effect of new treatments for cancer on mortality has been 
largely disappointing.”  A recent Fortune magazine article was entitled, “Why we’re 
losing the war on cancer, and how to win it” (Leaf (2004)).  
  But the stagnancy of the cancer mortality rate is potentially misleading.  This 
mortality rate depends on two distinct factors: the probability of being diagnosed with 
cancer, and cancer survival rates—the probability of not dying t years after being 
diagnosed with cancer (t = 1, 2, …).  As Figure 2 reveals, the cancer incidence rate—the 
number of new cancer cases per 100,000 people—increased sharply from 1975-1979 to 
1992.  Although it declined after 1992, it was still 16% higher in 2000 than it was in 
1975-1979.  The long-run increase in cancer incidence is presumably primarily 
attributable to the decline in mortality from other causes, particularly cardiovascular 
disease.  Medical advances for diseases other than cancer have reduced the risk of dying 
from those diseases, and have thereby increased the risk of developing cancer.  
According to the National Cancer Institute, in the year 2000 the lifetime risk of 
developing cancer was about 40%. 
                                                 
1 Cancer Facts and the War on Cancer. 
2  http://www.cdc.gov/nchs/data/hus/tables/2003/03hus030.pdf  In 1980, cancer caused less premature 
mortality than heart disease.  In 2001, cancer caused 35% more premature mortality than heart disease.   
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Although cancer incidence has increased, so has cancer survival.3   Figure 3 
shows the five-year relative survival rate from all malignant cancers from 1975-1979 to 
1995.  The probability that a person diagnosed with cancer in 1975-1979 would not die 
from causes associated specifically with the given cancer within 5 years was 50.0%.  For 
a person diagnosed with cancer in 1995, that probability was 25% higher: 62.7%.   
Figure 4 summarizes the trends in cancer mortality, incidence, and survival.  The 
relative stability of the cancer mortality rate is the result of two offsetting trends: an 
increase in the cancer incidence rate, and an increase in the relative survival rate (or a 
decrease in the relative non-survival rate).   
This paper’s main objective is to assess the contribution of pharmaceutical 
innovation to the increase in cancer survival rates.  I estimate that only about one third of 
the approximately 80 drugs currently used to treat cancer had been approved when the 
war on cancer was declared.  In other words, there has been a threefold increase in the 
size of the cancer drug armamentarium in the last three decades.4   
Some clinical trials of cancer agents have demonstrated survival benefits.  For 
example, one study showed that the two-year survival rate of non-Hodgkin’s lymphoma 
patients treated with standard chemotherapy and rituximab (approved by the FDA in 
1997) was 70%, while that of patients treated with standard chemotherapy alone was only 
57%.5  Another study showed that women who were treated with epirubicin (approved by 
the FDA in 1999) were 31% per cent less likely to relapse or die within five years than 
women treated with standard chemotherapy alone.6  A recent study7 reported that 
“standard chemotherapy and hormone treatment work even better than researchers had 
expected…For middle-aged women with an early stage of the disease, combining the 
                                                 
3 Epidemiologists calculate two kinds of survival rates: observed and relative survival rates. The observed 
survival rate represents the proportion of cancer patients surviving for a specified time interval after 
diagnosis. Some of those not surviving died of the given cancer and some died of other causes.  The 
relative survival rate is calculated using a procedure (Ederer et al., 1961) whereby the observed survival 
rate is adjusted for expected mortality. The relative survival rate approximates the likelihood that a patient 
will not die from causes associated specifically with the given cancer before some specified time after 
diagnosis. It is always larger than the observed survival rate for the same group of patients. 
4 The growth rate of the cumulative stock of approved cancer drugs has been greater than the growth rate of 
the cumulative stock of drugs approved for other diseases. 
5 “New England Journal of Medicine highlights survival benefit of new treatment for non-Hodgkin’s 
lymphoma,” http://www.eurekalert.org/pub_releases/2002-01/k-nej012202.php 
6 “Drug regime boosts breast cancer survival,” http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/2946530.stm 
7 “Therapies Cut Death Risk, Breast-Cancer Study Finds,” New York Times, 13 May 2005. 
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treatments can halve the risk of death from breast cancer for at least 15 years.  For 
instance, a woman under 50 with a tumor big enough to feel, but not invading her lymph 
nodes, would have a 25 percent risk of dying of breast cancer in the next 15 years if she 
had surgery but no drug therapy. Adding both chemotherapy and hormone treatment 
would drop her risk to 11.6 percent.” 
However, Johnson et al (2003) report that only 25% of FDA cancer drug 
approvals are based on demonstrated survival benefits: “end points other than survival 
were the approval basis for 68% (39 of 57) of oncology drug marketing applications 
granted regular approval and for all 14 applications granted accelerated approval from 
January 1, 1990 to November 1, 2002.”8 
In this paper I will try to estimate the average or aggregate effect of 
pharmaceutical innovation on cancer survival.  I recognize, of course, that pharmaceutical 
innovation is just one of a number of factors that may have contributed to the increase in 
cancer survival.  Other potential factors include: a changing mix of cancers over time; 
technological advances in diagnostic procedures that led to earlier detection and 
diagnosis; and changes in non-pharmaceutical cancer treatment (surgery and radiation).  
The available data will enable me to control for these factors to a very great extent. 
The survival rate data shown in Figure 3 are for all cancers combined.  The mix of 
cancers changes over time as the incidence of some cancers increases and the incidence 
of others decreases.  Annual growth rates during the period 1950-2000 of the incidence of 
various cancers are shown in Figure 5.   Incidence of two cancers—lung and bronchus 
(among females) and melanoma—increased more than 4% per year, while incidence of 
stomach and cervix uteri cancer declined more than 2% per year.  Moreover, there is 
considerable variation in survival rates across cancers.  As shown in Figure 6, in 1950, 
seven cancers had 5-year relative survival rates above 50%, while seven had rates at or 
below 10%.9  In principle, the increase in the survival rate for all cancers combined could 
be partly due to an increase in the relative incidence of cancers with high (initial) survival 
rates.  In practice, this is not the case.  As shown in Figure 7, there is essentially no 
                                                 
8 Regular approval is based on end points that demonstrate that the drug provides a longer life, a better life, 
or a favorable effect on an established surrogate for a longer life or a better life.  Accelerated approval is 
based on a surrogate end point that is less well established but that is reasonably likely to predict a longer 
or a better life. 
9 The 5-year relative survival rate for all cancers combined in 1950 was 35.0%. 
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relationship across cancers between the survival rate in 1950-54 and the 1950-2000 
growth rate of incidence.10   
Survival data, by cancer site, of the type shown in Figure 6 can be calculated for 
different periods.  Cancer site-specific survival data (for whites only) for 1950-54 and 
1992-99 are shown in Table 1 and Figure 8.  In the figure, note that every point lies above 
the 45o line: for every cancer site, the 1992-99 survival rate was greater than the 1950-54 
survival rate.  However the percentage increase in the survival rate varied considerably 
across cancer sites.  For example, the 1950-54 survival rate for both brain and other 
nervous system cancers and childhood cancers was about 20%, but the 1992-99 survival 
rate was 32.1% for the former and 78.7% for the latter.  Similarly, the survival rate for 
colon cancer increased from 41% to 63%, while the survival rate from prostate cancer 
increased from 43% to 98%.  I hypothesize that these differential rates of progress are 
partly attributable to different rates of pharmaceutical innovation for different types of 
cancer. 
To test this hypothesis within a “differences in differences” framework, I will 
estimate models of cancer mortality rates using longitudinal, annual, cancer-site-level 
data based on large samples of people diagnosed with cancer during the period 1975-
1995.  The explanatory variable of primary interest is the (lagged value of the) 
cumulative number of cancer drugs approved to treat that cancer type.  The following 
covariates will be included in the model: fixed cancer site effects, fixed year effects, 
incidence, stage distribution of diagnosed patients, mean age at diagnosis, percent of 
patients having surgery, and percent of patients having radiation.  Including these 
variables is likely to control for the effect of technological advances in diagnostic 
procedures.  As noted in the SEER Cancer Statistics Review, “improved earlier detection 
and diagnosis of cancers may produce an increase in both incidence rates and survival 
rates.”  To the extent that these improvements apply to all forms of cancer, their effects 
are captured by the fixed year effects.  Cancer-site-specific improvements in detection 
                                                 
10 This confirms the observation that “while it is possible to adjust the survival rate for all cancers 
combined on the basis of the relative frequency of each specific cancer in some specified reference period, 
rates adjusted in this manner differ by only a small amount from unadjusted rates.”   (SEER Cancer 
Statistics Review, p. 13.) 
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and diagnosis are likely to lead to reductions in age at date of diagnosis, to increased 
measured incidence, and to diagnosis at an earlier stage.   
Figure 9 depicts the general model that we will estimate.  Section I of the paper 
describes the data that will be used to estimate the model.  Section II describes the 
econometric specification and procedure.  Estimates of the model are presented in 
Section III.  Interpretation and implications of the estimates are considered in Section IV.   
In addition to the longitudinal, cancer-site-level analysis of U.S. data, in Section 
V I will analyze international, cancer-site-level data for the year 2000.  I will investigate 
the effect of availability of new drugs on survival from 17 types of cancer in over 35 
countries, by estimating a model that include both fixed cancer-type effects and fixed 
country effects; these control for all determinants of cancer survival that are invariant 
across cancer types within a given country, and that are invariant across countries for a 
given cancer type.  Section VI contains a summary. 
 
I.  Data 
 
The National Cancer Act of 1971 mandated the collection, analysis, and 
dissemination of data useful in the prevention, diagnosis, and treatment of cancer. This 
mandate led to the establishment of the Surveillance, Epidemiology, and End Results 
(SEER) Program of the National Cancer Institute (NCI). A continuing project of the NCI, 
the population-based cancer registries participating in the SEER Program routinely 
collect data on all cancers occurring in residents of the participating areas.  Trends in 
cancer incidence and patient survival in the U.S. are derived from this database.  The 
SEER Program is a sequel to two earlier NCI programs — the End Results Program and 
the Third National Cancer Survey.  
The SEER Program is considered as the standard for quality among cancer 
registries around the world. Quality control has been an integral part of SEER since its 
inception. Every year, studies are conducted in the SEER areas to evaluate the quality and 
completeness of the data being reported (SEER's standard for case ascertainment is 98 
percent). In some studies, a sample of cases is reabstracted to evaluate the accuracy of 
each of the data elements collected from the medical records. In other studies, targeted 
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information gathering is performed to address specific data quality needs. Computer edits 
also are used by registries to ensure accurate and consistent data. 
The initial SEER reporting areas were the States of Connecticut, Iowa, New 
Mexico, Utah, and Hawaii; the metropolitan areas of Detroit, Michigan, and San 
Francisco-Oakland, California; and the Commonwealth of Puerto Rico. Case 
ascertainment began with January 1, 1973, diagnoses.  In 1974-1975, the program was 
expanded to include the metropolitan area of New Orleans, Louisiana, the thirteen-county 
Seattle-Puget Sound area in the State of Washington, and the metropolitan area of 
Atlanta, Georgia. New Orleans participated in the program only through the 1977 data 
collection year. In 1978, ten predominantly black rural counties in Georgia were added. 
American Indian residents of Arizona were added in 1980. In 1983, four counties in New 
Jersey were added with coverage retrospective to 1979. New Jersey and Puerto Rico 
participated in the program until the end of the 1989 reporting year. The National Cancer 
Institute also began funding a cancer registry that, with technical assistance from SEER, 
collects information on cancer cases among Alaska Native populations residing in 
Alaska. In 1992, the SEER Program was expanded to increase coverage of minority 
populations, especially Hispanics, by adding Los Angeles County and four counties in the 
San Jose-Monterey area south of San Francisco. In 2002, the SEER Program expanded 
coverage to include Kentucky and Greater California (the counties of California that were 
not already covered by SEER). Also in 2002, New Jersey and Louisiana became SEER 
participants again.  Figure 10 is a map of SEER cancer registries. 
Data from the 9 SEER geographic areas used in this study represent, respectively, 
approximately 10 percent of the U.S. population.  By the end of the 1999 diagnosis year, 
the database contained information on over 3,200,000 cases diagnosed since 1973.  Over 
170,000 new cases are added annually. 
Data contained in the SEER Public Use File (PUF) enable us to characterize a group 
of people diagnosed with a given type of cancer in a given year.  They may be 
characterized in terms of: 
• Their future survival prospects 
• The size of the group (incidence) 
• Their age distribution 
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• Their distribution by extent/severity of illness (cancer stage distribution) 
• Whether their initial treatment included surgery and/or radiation 
Future survival prospects.  Each record in the SEER Public-Use File indicates 
whether the person had died by the cutoff date for this file (December 31, 2000), and if 
so, the date of death.  This allows us to compute, for each cancer site and year of 
diagnosis, the survival distribution function (SDF) and several closely related functions.  
The SDF evaluated at t is the probability that a member of the population will have a 
lifetime exceeding t, that is S(t) = Prob(T > t), where S(t) denotes the survival function 
and T is the lifetime of a randomly selected experimental unit.  Some functions closely 
related to the SDF are the cumulative distribution function (CDF), the probability density 
function (PDF), and the hazard function.  The CDF F(t) is defined as 1 – S(t) and is the 
probability that a lifetime is smaller than t.  The PDF denoted f(t) is defined as the 
derivative of F(t), and the hazard function denoted h(t) is defined as f(t)/S(t).  Hence h(t) 
= -S’(t)/S(t), where S’(t) is the derivative of S(t).  The hazard rate is the percentage 
reduction in the survival rate.)  Discrete time: h(t) = (S(t) – S(t+1))/S(t) Î S(t) = ∏j=0t-1 
(1 – h(j))) 
 To illustrate, Figure 11 shows estimates of the survival and hazard functions of 
people diagnosed with all types of cancer in 1975.11  The 5-year survival rate was 45%, 
and the 10-year survival rate was 34%.  The hazard rate declines very sharply during the 
first several years.  The probability of dying, conditional on being alive at the beginning 
of the year, is 31% in the first year, 15% in the second year, and 10% in the third year.  It 
declines much more slowly during the next five years, when it levels off at about 5%. 
 We compute hazard functions of this type for each cancer site and year of 
diagnosis.12  That is, we compute estimates of HAZARDi,t-k,t: the hazard rate from year t 
to year t+1 of people diagnosed with cancer type i in year t-k (i = 1,…,30; t = 
1975,…,2000; k=1,…,24).  For example, suppose i = breast cancer, t = 1990, and k = 5.  
Then HAZARDi,t-k,t = the probability that a woman diagnosed with breast cancer in 1985 
                                                 
11 These survival and hazard rates, like all others we will compute and analyze, are observed rather than 
relative rates.  However, the models we will estimate will include covariates (e.g. fixed diagnosis-year 
effects and mean age at diagnosis) that presumably effectively adjust for changes in “expected mortality”. 
12 These are computed using the LIFETEST procedure (LIFETABLE method) in SAS. 
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died in 1990, conditional on surviving until the beginning of 1990.  We also compute 
standard errors of these estimates.   
Incidence.  Incidence of cancer type i in year t can be estimated by simply 
counting the number of cases in the SEER PUF.  The incidence rate is the number of new 
cases per year per 100,000 persons:  
INCIDENCEit = CASESit / POPt 
Hence ln(INCIDENCEit) = ln(CASESit) – ln(POPt) 
        = ln(CASESit) + δt 
where δt =  – ln(POPt).  Including ln(CASESit) and a set of diagnosis-year dummies (δt‘s) 
therefore controls for site-specific changes in cancer incidence.  As observed in the 
National Cancer Institute’s SEER Cancer Statistics Review, 1975-2000, “the improved 
earlier detection and diagnosis of cancers may produce an increase in both incidence 
rates and survival rates.”13  Hence including ln(CASESit) and a set of diagnosis-year 
dummies (δt‘s) in cancer survival or hazard models may control, to an important extent, 
for the effects of changes (improvements) in cancer detection and diagnosis. 
Cancer stage.  In addition to cancer site, each SEER record indicates cancer stage at 
the time of diagnosis.  There are four main cancer stage categories:14 
• In situ (Stage 0)—A noninvasive neoplasm; a tumor which has not penetrated the 
basement membrane nor extended beyond the epithelial tissue. Some synonyms 
are intraepithelial (confined to epithelial tissue), noninvasive and noninfiltrating. 
• Localized (Stage 1)—An invasive neoplasm confined entirely to the organ of 
origin.  It may include intraluminal extension where specified. For example for 
colon, intraluminal extension limited to immediately contiguous segments of the 
large bowel is localized, if no lymph nodes are involved. Localized may exclude 
invasion of the serosa because of the poor survival of the patient once the serosa 
is invaded. 
• Regional (Stage 2)—A neoplasm that has extended 1) beyond the limits of the 
organ of origin directly into surrounding organs or tissues; 2) into regional lymph 
nodes by way of the lymphatic system; or 3) by a combination of extension and 
regional lymph nodes. 
• Distant (Stage 4)—A neoplasm that has spread to parts of the body remote from 
the primary tumor either by direct extension or by discontinuous metastasis (e.g., 
                                                 
13 http://seer.cancer.gov/csr/1975_2000/results_merged/sect_01_overview.pdf 
14 There are two additional categories: Localized/Regional (Stage 8)—Only used for Prostate cases, and 
Unstaged (Stage 9)—Information is not sufficient to assign a stage.  All lymphomas and leukemias are 
considered unstaged (code `9'). 
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implantation or seeding) to distant organs, issues, or via the lymphatic system to 
distant lymph nodes. 
 
Survival rates of patients diagnosed in a given year are strongly inversely related to 
cancer stage, e.g. patients with Stage 4 cancer have much lower survival rates than 
patients with Stage 0 cancer.  In principle, therefore, it might seem desirable to calculate 
survival rates by site, diagnosis year, and stage, rather than merely by site and diagnosis 
year.  However due to a phenomenon known as stage migration, analysis of survival rates 
and other variables by site, diagnosis year, and stage is likely to lead to erroneous 
inferences.   
The assignment of a given stage to a particular cancer may change over time due 
to advances in diagnostic technology. Stage migration occurs when diagnostic procedures 
change over time, resulting in an increase in the probability that a given cancer will be 
diagnosed in a more advanced stage. For example, certain distant metastases that would 
have been undetectable a few years ago can now be diagnosed by a computer tomography 
(CT) scan or by magnetic resonance imaging (MRI). Therefore, some patients who would 
have been diagnosed previously as having cancer in a localized or regional stage are now 
diagnosed as having cancer in a distant stage.  The likely result would be to remove the 
worst survivors — those with previously undetected distant metastases — from the 
localized and regional categories and put them into the distant category.  As a result, the 
stage-at-diagnosis distribution for a cancer may become less favorable over time, but the 
survival rates for each stage may improve: the early stage will lose cases that will survive 
shorter than those remaining in that category, while the advanced stage will gain cases 
that will survive longer than those already in that category.  However, overall survival 
would not change (Feinstein et al., 1985).  Stage migration is an important concept to 
understand when examining temporal trends in survival by stage at diagnosis as well as 
temporal trends in stage distributions; it could affect the analysis of virtually all solid 
tumors.15 
 Among people diagnosed with the same kind of cancer in the same year, those 
with later stage cancer always have lower survival rates.  But, as we will show below, 
                                                 
15 SEER Cancer Statistics Review 1973-1999 Overview, p. 12. 
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increases in the share of patients with later-stage cancer are not always associated with a 
reduction in the survival rate of that group.  
 Since stage migration is very likely to result in misleading statistics for cancer 
survival by stage, we will measure survival by cancer site and diagnosis year, rather than 
by cancer site, diagnosis year, and stage.  However, we will control for the effect of 
changes in the measured stage distribution by including stage distribution variables (e.g., 
the % of cases that are Stage 0 cases) as covariates. 
Cancer treatment.  The medical community recognizes three types of 
conventional cancer treatment: surgery, radiation therapy, and drugs.   
Surgery.  Surgery is often the first step in cancer treatment because it is used both 
to diagnose and to treat cancer.  Surgery alone sometimes cures cancer. Sometimes it is 
used in conjunction with other treatments such as chemotherapy (cancer drugs) or 
radiation therapy.  More than half of the people diagnosed with cancer will have some 
type of surgery or operation at some point.  Surgery is used to remove tumors confined to 
a small space. Surgery is also used to reduce the size of large tumors so that follow-up 
treatment by radiation therapy or chemotherapy will be even more effective. 
From the SEER PUF, we can determine whether the patient’s "first course of 
treatment" included surgery.  The "first course of treatment" is either the planned course 
of treatment stated in the medical record, or the standard treatment for that site and extent 
of disease when there is no treatment plan in the chart.  In general terms, first course of 
treatment extends through the end of the planned treatment, or until there is evidence of 
treatment failure (progression of disease), and the patient is switched to another type of 
treatment. 
Radiation. Radiation therapy uses radiation (high-energy rays) to kill or shrink 
tumor cells. It is used to treat some, but not all cancers.  Radiation therapy destroys cells 
either directly or by interfering with cell reproduction. Normal cells are able to recover 
from radiation damage better than cancer cells.  Used alone, radiation therapy can be 
curative in many cases.  It is also used in combination with other treatments/therapies 
such as surgery. It might be used both to reduce the size of tumors before surgery and to 
destroy any remaining cancer cells after surgery.  Radiation therapy is also used with 
many other conventional cancer treatments such as chemotherapy and hormone therapy.  
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When cure is not possible, radiation therapy can also help alleviate symptoms such as 
pain, and improve quality of life for patients.  From the SEER PUF, we can also 
determine whether the patient’s "first course of treatment" included radiation.   
Chemotherapy.  According to the SEER Program Code Manual, data on 
chemotherapy, hormone therapy, and immunotherapy are collected in SEER.  With 
respect to chemotherapy, cancer registries are asked to “code any chemical [that] is 
administered to treat cancer tissue and which is not considered to achieve its effect 
through change of the hormone balance.”   
Unfortunately, the SEER Public Use File does not contain any information about 
chemotherapy.  According to NCI staff, this is because chemotherapy is generally not 
performed in an inpatient hospital setting—it is usually performed in an outpatient 
hospital setting, in a physician’s office, or at home.  Chemotherapy data collected by 
SEER are rather incomplete, so SEER does not include the information on the public use 
file.16  I therefore constructed a cancer-site-specific and year-specific chemotherapy 
variable--the cumulative number of drugs approved to treat each type of cancer in each 
year--by combining data from two sources.   
The first source is the Cancer Drug Manual produced by the British Columbia 
Cancer Agency, Division of Pharmacy (de Lemos (2004)).  The Professional Drug Index 
contains monographs on 83 cancer drugs.  The monographs were written, reviewed and 
edited by pharmacists practicing in oncology settings, and have been reviewed by 
oncologists and an oncology nurse clinician.  Each monograph contains a section on the 
uses of the drug.  For example, according to the monographs, there are seven uses for 
asparaginase (acute lymphocytic leukemia, acute myeloblastic leukemia, acute 
myelomonocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, 
melanosarcoma, and non-Hodgkin's lymphoma), and four for dacarbazine (Hodgkin's 
disease, malignant melanoma, neuroblastoma, and soft tissue sarcomas).  Using the 
information contained in all 83 monographs, I constructed a list of drugs used to treat 
each kind of cancer.  I determined, for example that the following 12 drugs are used 
today to treat bladder cancer: bcg, carboplatin, cisplatin, doxorubicin, fluorouracil, 
                                                 
16 E-mail communication from April Fritz, Manager, Data Quality, SEER Program, 8 January 2004. 
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gemcitabine, interferon alfa, methotrexate, mitomycin, porfimer, thiotepa, and 
vinblastine.   
I used a second data source—Mosby’s Drug Consult—to determine the year in 
which the FDA approved each of these drugs.17  This enabled me to track the cumulative 
number of drugs approved by the FDA for each cancer type for each year.   
 As Figure 12 indicates, the rate of increase of the stock of drugs varies 
considerably across cancer sites in a given period, and also across periods for a given 
cancer site.  For example, between 1969 and 2002, there was a 4.4-fold increase in the 
stock of drugs for breast cancer, and an 8-fold increase in the stock of drugs for prostate 
cancer.  Also, the stock of drugs for colon and rectum cancer remained constant from 
1974 to 1980, but then doubled from 1980 to 1982.   
 
II.  Econometric Model 
 
For each cancer site and year of diagnosis (1975-1995), I computed a hazard 
function.  For people diagnosed in 1975, the hazard function had 25 points—one for each 
of the years 1-25 (the cutoff date for the SEER PUF is Dec. 31, 2000).  For people 
diagnosed in 1976, the hazard function had 24 points, and so forth.  For people diagnosed 
in 1995, the hazard function had just 5 points.   
I estimated a separate model of the hazard rate for each of the k years after 
diagnosis (k = 1, 2,…, 25): a model of the first-year hazard rate, the second-year hazard 
rate, etc.  Each model was of the following form: 
ln(HAZARDi,t-k,t) = αik + δtk + β1k ln(DRUG_STOCKi,t-3) + β2k ln(Ni,t-k)  
+ β3k AGE_MEANi,t-k + β4k SURGERY%i,t-k + β5k RADIATION%i,t-k  
+ θ0k STAGE0%i,t-k + θ1k STAGE1%i,t-k + θ2k STAGE2%i,t-k  
+ θ4k STAGE4%i,t-k + θ8k STAGE8%i,t-k + εi,t-k,t      (1) 
where:  
HAZARDi,t-k,t  = the hazard rate from year t to year t+1 of people diagnosed with 
cancer type i in year t-k.18   
                                                 
17 The list of cancer drugs, in order of year of FDA approval, is shown in Appendix Table 1. 
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DRUG_STOCKi,t-3  = the cumulative number of drugs approved by the end of year t-3 
that are (currently) used to treat cancer type i. 
Ni,t-k  = the number of people diagnosed with cancer type i in year t-k.   
AGE_MEANi,t-k  = the mean age of people diagnosed with cancer type i in year t-k.   
SURGERY%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose initial treatment included surgery 
RADIATION%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose initial treatment included radiation 
STAGE0%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose cancer was classified as stage 0 (in situ). 
STAGE1%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose cancer was classified as stage 1 (localized) 
STAGE2%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose cancer was classified as stage 2 (regional) 
STAGE4%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose cancer was classified as stage 4 (distant) 
STAGE8%i,t-k  = the fraction of people diagnosed with cancer type i in year t-k 
whose cancer was classified as stage 8 (localized/regional-prostate 
only) 
 
Table 2 presents some summary statistics, by year of diagnosis, from the SEER 
Public Use File (PUF).  There appear to be sharp breaks in several of the series between 
1974 and 1975 and again between 1995 and 1996.  We therefore restricted the sample to 
include only the 2.1 million people diagnosed with cancer during the years 1975-1995. 
In eq. (1), the hazard rate in year t for patients diagnosed with cancer type i in 
year t-k is a function of: fixed cancer-site effects, fixed diagnosis-year effects, the stock 
of drugs approved to treat that type of cancer by the end of year t-3, cancer incidence, 
mean age at diagnosis, extent of surgery and radiation,19 and cancer stage distribution.  
Since the dependent variable is the logarithm of the hazard rate, we are, in effect, 
estimating a proportional hazards model.   Such a model assumes that changing an 
explanatory variable has the effect of multiplying the hazard rate by a constant.  
                                                                                                                                                 
18 For example, suppose i = breast cancer, t = 1990, and k = 5.  Then HAZARDi,t-k,t= the probability that a 
woman diagnosed with breast cancer in 1985 died in 1990, conditional on surviving until the beginning of 
1990. 
19 Ideally, we would like to measure the number (and importance) of surgical and radiological innovations, 
analogous to the number of pharmaceutical innovations.  Since the FDA does not regulate surgery and 
radiology in the same way that it regulates drugs, this is not feasible.  However changes in the frequency of 
surgery, for example, may be highly correlated with surgical innovation.  If there are more surgical 
innovations for one cancer site than there are for another, one would expect a greater increase (or smaller 
decline) in surgical treatment of the former site. 
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Introduced by D. R. Cox (1972),20 the proportional hazards model was developed in order 
to estimate the effects of different covariates influencing the times-to-failure of a system, 
and has been widely used in the biomedical field.   
We assume that the log of the hazard rate depends on the log of the lagged stock 
of drugs.  Eq. (1) may be considered a health production function, and production 
functions are often assumed to be log-linear, consistent with the hypothesis of 
diminishing marginal productivity of inputs.  For example, in his model of endogenous 
technological change, Romer (1990) hypothesized the production function  
ln Y = (1-α) ln A  + (1-α) ln L + α ln K,  
where Y = output, A = the “stock of ideas”, L = labor used to produce output, K = capital, 
and 0 < α < 1.  The cumulative number of drugs approved (DRUG_STOCK) is 
analogous to the stock of ideas. 
 In principle, the hazard rate could depend on the number of drug classes, as well 
as (or instead of), the number of drugs.  For example, introducing a drug that is the first 
in its class might have a greater impact on the hazard rate than introducing a drug that is 
the fifth in its class.  We will test for this by estimating versions of the model that include 
the number of drug classes as well as the number of drugs.21 
 Inclusion of fixed cancer-site and year effects means that we are comparing the 
(percentage) changes in hazard rates of different cancer sites during the same period.  
Estimates of β1k that are negative and significantly different from zero would signify that 
there were above-average declines in the hazard rates of cancer sites with above-average 
increases in the stock of drugs, ceteris paribus.   
 Instead of modeling hazard rates, one could model survival rates.  Since, by 
definition, Ht = (St – St+1)/ St, where Ht denotes the hazard rate during period t and St 
denotes the percent surviving until the beginning of period t,  
Sn = (1 – H1) * (1 – H2) * … * (1 – Hn-1) 
The probability of surviving until the beginning of year n is the product of one minus the 
hazard rate of years 1 through n-1.22  For example, the 10-year survival rate of patients 
diagnosed in 1975 depends on their hazard rates during 1975-1984.  Suppose a new drug 
                                                 
20 See also Cox and Oakes (1984). 
21 The distribution of drugs, by drug class, is shown in Appendix Table 2. 
22 This also implies that ln Sn = Σin-1 ln (1 – Hi) ≈ - Σin-1 Hi 
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was approved in 1980.  This would be expected to reduce hazard rates after 1980 (or even 
later, due to diffusion lags, discussed below), but not before that date.  For this reason, to 
pinpoint the effect of new drug approvals, modeling annual hazard rates is more 
appropriate than modeling multi-year survival rates. 
 There is ample evidence that, after a new drug is approved, it takes a few years for 
that drug to be widely utilized.  This may be illustrated using the following data on the 
U.S. sales ranks of two major (non-cancer) drugs approved during the 1990s.23 
U.S. sales rank: Alendronate (Fosamax)
Approved in 1995
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U.S. sales rank: Atorvastatin (Lipitor)
Approved in 1996
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It took at least 3 years for each of these drugs to attain its peak sales rank.  It therefore 
seems sensible to hypothesize a lag of about three years in the impact of the stock of 
                                                 
23 Source: NDC Health, as reported on http://www.rxlist.com/top200.htm. 
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approved drugs on the hazard rate.  I estimated the model with alternative assumed lags 
(1 to 4 years).  Assuming a 3-year lag yielded the best fit.  These are the estimates I will 
report in the next section. 
 
III.  Estimates 
 
Estimates of eq. (1), by number of years after diagnosis (1,2,…,8) , are reported in 
Table 3.   All equations included 30 cancer-site fixed effects and year fixed effects.  The 
hazard models for the first six years (after diagnosis) were estimated using data on people 
diagnosed during 1975-1995, and included fixed effects for each of those years.  Starting 
seven years after diagnosis, the sample period was reduced by one year for each year 
after diagnosis.  For example, the year-7 hazard model was estimated using data on 
people diagnosed during 1975-1994 (due to censoring of the data after 12/31/2000).    
All equations were estimated by weighted least squares, weighting by the reciprocal of 
the estimated variance of the hazard rate. 
 The estimates shown in lines 1-10 are of the first-year hazard model, i.e. the 
hazard rate in the first year after diagnosis.  The estimate of the coefficient on the lagged 
drug-stock is negative and highly statistically significant (line 1).  This indicates that 
cancers for which the stock of drugs increased more rapidly tended to have larger 
declines in the first-year hazard rate (and larger increases in the one-year survival rate).  
During the period 1975-1995, the incidence-weighted mean increase in 
ln(DRUG_STOCKi,t-3) was 1.31.  (The stock of drugs increased 3.7-fold.)  This implies 
that the 1975-1995 increase in the stock of drugs reduced the first-year hazard rate by 
about 22% (= .167 * 1.31).  As shown in Figure 11, in 1975, the first-year hazard rate 
was 30.6%.  Hence, we estimate that the 1975-1995 increase in the stock of drugs 
reduced the first-year hazard rate from 30.6% to 23.9%. 
 We consider next the coefficients on the other regressors in the first-year hazard 
model.  The coefficient on ln(Ni,t-k) is negative and highly significant (line 2), indicating 
that cancers with the highest growth of SEER incidence had the greatest declines in the 
first-year hazard rate.  This may reflect the fact that cancers with the highest growth of 
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SEER incidence had the greatest improvements in early detection and diagnosis.  As the 
NCI observes, “The improved earlier detection and diagnosis of cancers may produce an 
increase in both incidence rates and survival rates. These increases can occur as a result 
of the introduction of a new procedure to screen subgroups of the population for a 
specific cancer; they need not be related to whether use of the screening test results in a 
decrease in mortality from that cancer. As the proportion of cancers detected at screening 
increases, presumably as a result of increased screening of the population, patient 
survival rates will increase, because they are based on survival time after diagnosis.” 
 Not surprisingly, the coefficient on AGE_MEANi,t-k is positive and highly 
significant (line 3): cancers with larger increases in mean age at diagnosis had smaller 
reductions in first-year hazard rates.24   
 The coefficient on SURGERY%i,t-k is negative and highly significant (line 4).  
This indicates that cancers with greater increases in the probability of surgical treatment 
had greater reductions in the first-year hazard rate.  However, the coefficient on 
RADIATION%i,t-k is not significantly different from zero (line 5).   
 The last estimates to consider in the first-year hazard model are the coefficients 
on the stage-distribution variables (lines 6-10).  As one might expect, the stage 4 
coefficient is larger than the stage 2 coefficient, which is larger than the stage 1 
coefficient.  This indicates that a shift to later stages increases the first-year hazard rate.  
However the stage 1 coefficient is smaller than the stage 0 coefficient.  This indicates that 
a shift from stage 0 (in situ) cancers to stage 1 (localized) cancers is associated with a 
reduction in the hazard rate.  This is presumably due to differential rates of stage 
migration for different types of cancers. 
 Estimates of the second-year hazard model are shown in lines 12-21.  In most 
respects, this set is qualitatively similar to the first-year set.   Once again, the estimate of 
the coefficient on the lagged drug-stock is negative and highly statistically significant 
(line 12).  The only notable difference from the first-year estimates is that the coefficient 
on RADIATION%i,t-k is now positive and significant (line 16).  This indicates that 
cancers with greater increases in the probability of radiation treatment had smaller 
reductions in the second-year hazard rate.   
                                                 
24 What is surprising, however, is that mean age at diagnosis increased from 61.4 in 1975 to 62.7 in 1995.   
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 In the third-year hazard model estimates (lines 23-32), the coefficient on the 
lagged drug-stock is negative and similar in magnitude to the coefficients in the first two 
years, but is only marginally significant (p-value = 0.08).  As in the estimates for the 
previous two years, the hazard rate increases with respect to age at diagnosis, and 
declines with respect to incidence and surgical intervention.   The radiation variable is 
insignificant, and the stage-distribution coefficients (for stages 0-4) have their expected, 
monotonic profile. 
 In the fourth-year hazard model estimates (lines 34-43), the coefficient on the 
lagged drug-stock is positive and its magnitude is large (0.48), which is inconsistent with 
our hypothesis.  However, the mean hazard rate in year 4 is substantially lower than it is 
in previous years, and we will show below that this large positive effect offsets only a 
small part of the negative effects of the drug stock on the hazard rates in years 1-3.   
The remainder of Table 3 shows estimates of the hazard model in years 5-8.  To 
summarize, in the first eight years, the coefficient on the drug stock is negative three 
times as often as it is positive, and it is negative and significant twice as often as it is 
positive and significant.   Moreover, the coefficient on the drug stock is negative in the 
first three years (and significant in the first two), when the hazard rate is highest. 
We estimated models that included the log of the number of drug classes in year t-
3, as well as the log of the number of drugs in year t-3.  In general, the coefficient on the 
drug-class variable was far from statistically significant, and inclusion of this variable 
had virtually no effect on the estimates of β1k.  This suggests that the introduction of a 
first-in-class drug does not increase cancer survival more than the introduction of 
subsequent drugs within the class (over and above the general effect of diminishing 
marginal productivity).   
 
IV.  Interpretation and Implications of Estimates 
 
 We can use the estimates of the drug-stock coefficients for all years (years 1-23) 
to assess the effect of new drug introductions on the entire cancer survival distribution 
function and on life expectancy at time of diagnosis.  We begin with the vector of 1975 
hazard rates shown in Figure 11.  These reflect the prevailing conditions at that time: the 
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distribution of cancers by site and stage, average age of patients diagnosed, percent of 
patients receiving surgery and radiation, etc.  They also reflect the drugs that were 
available at that time.   
 We then use our estimates to “predict” hazard rates in 1995, given the drugs 
available in 1995, if all other conditions had remained the same as they had been in 1973.  
The predicted k-year hazard rate (HAZ_PREk) is computed as follows: 
HAZ_PREk = HAZ_ACTk * (1 + β1k Δln(DRUG_STOCKt-3)) 
where HAZ_ACTk is the actual 1975 k-year hazard rate and Δln(DRUG_STOCKt-3) is 
the 1975-1995 change in the incidence-weighted mean of ln(DRUG_STOCKi,t-3).  As 
noted above, this is equal to 1.31.  Hence  
HAZ_PREk = HAZ_ACTk * (1 + (1.31* β1k)). 
 From the vectors of actual and predicted hazard rates, we can compute vectors of 
actual and predicted survival rates: 
SURV_ACTn = (1 – HAZ_ACT1) * (1 – HAZ_ACT2) * … * (1 – HAZ_ACTn-1) 
SURV_PREn =  (1 – HAZ_PRE1) *  (1 – HAZ_PRE2) * … * (1 – HAZ_PREn-1) 
These calculations are shown in Table 4.  Columns 1-4 show the estimates of β1k 
for k =1,2,…,24.  Actual 1975 hazard rates (HAZ_ACTk) are shown in column 5.  
Predicted 1975 hazard rates (computed as HAZ_PREk = HAZ_ACTk * (1 + (1.31* β1k))) 
are shown in column 6.  Actual and predicted 1975 survival rates are shown in columns 7 
and 8.  Actual 1995 survival rates for years 1-7 are shown in column 9.  The three vectors 
of survival rates are plotted in Figure 13.   
 Our estimates imply that, ceteris paribus—holding constant the cancer site- and 
stage-distribution, cancer incidence, mean age at diagnosis, and the probability of surgery 
and radiation—the 1975-1995 increase in the stock of drugs increased the 1-year cancer 
survival rate from 69.4% to 76.1%, the 5-year cancer survival rate from 45.5% to 51.3%, 
and the 10-year cancer survival rate from 34.2% to 38.1%. 
 From these figures, it appears that the increase in the stock of drugs accounted for 
a very large percentage of the actual increase in survival rates between 1975 and 1995.  
For example, the difference between 1-year predicted and actual 1975 survival rates 
(76.1% - 69.4%) is 91% of the actual increase in 1-year survival rates (76.7% - 69.4%).  
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But these are crude survival rates, not age-adjusted rates.25  The mean age of people 
diagnosed with cancer increased during the sample period.  As a result, the age-adjusted 
survival rate increased more than the crude survival rate.  Using methods similar to those 
described above, we can “predict” what the 1975 survival function would have been if 
mean age in 1975 had been the same as it was in 1995.  These are the calculations for 
years 1-6: 
Year 
1975 survival rate 
1975 survival rate if mean 
age same as in 1995 
1995 survival rate 
0 100.0% 100.0% 100.0%
1 69.4% 66.4% 76.7%
2 59.2% 55.9% 67.9%
3 53.2% 50.0% 62.6%
4 49.0% 45.8% 58.6%
5 45.5% 42.5% 55.2%
6 42.5% 39.8% 51.8%
 
Consequently, the increase in the stock of drugs accounted for a smaller percentage of the 
age-adjusted increase in survival rates than it did of the crude increase: 
Year 
% of increase in crude 
survival rate accounted for 
by increase in stock of drugs 
% of increase in age-adjusted 
survival rate accounted for by 
increase in stock of drugs 
1 91% 65% 
2 92% 66% 
3 88% 66% 
4 47% 35% 
5 60% 46% 
6 74% 57% 
 
 Although the surgical treatment rate (SURGERY%) had a significant negative 
effect on hazard rates in a number of years, there was very little change in the overall 
surgical treatment rate during the sample period—it was actually slightly lower in 1995 
(62.6%) than it was in 1975 (63.4%).  Hence, our estimates imply that changes in the 
surgical treatment rate had a negligible impact on cancer survival rates during this period.  
                                                 
25 Since we include mean age as a covariate in eq. (1), βk is an estimate of the effect of the drug stock on 
the age-adjusted hazard rate. 
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The radiation treatment rate also remained almost constant (at about 27%); its impact on 
cancer survival rates also appears to have been negligible.   
The vectors of actual and predicted survival rates allow us to compute actual and 
predicted values of life expectancy at time of diagnosis: 
LE_ACT = Σk = 0 (k + 0.5) * (SURV_ACTk - SURV_ACTk+1) 
LE_PRE = Σk = 0 (k + 0.5) * (SURV_PREk - SURV_PREk+1) 
Since the cutoff date for the SEER PUF is 12/31/2000, for people diagnosed in 1975, the 
data are right-censored at 25 years.  About 17.5% of people diagnosed in 1975 were alive 
at the cutoff date.  For these people, we need to make an assumption about remaining life 
expectancy, and this assumption will affect the levels of LE_ACT and LE_PRE.  
However, because SURV_PRE25 is virtually equal to SURV_ACT25, this assumption will 
not affect the difference LE_PRE - LE_ACT.  Estimated values of LE_PRE, LE_ACT, 
and their difference, under three alternative assumptions about the longevity (from time 
of diagnosis) of people surviving past the cutoff date (L’) are as follows: 
L' LE_ACT LE_PRE difference 
27.5 9.13 10.15 1.02
30.0 9.56 10.59 1.03
35.0 10.44 11.47 1.03
 
If we assume that people diagnosed in 1975 who are alive at the end of 2000 die in 2005 
(30 years after diagnosis), then the actual life expectancy of all people diagnosed in 1975 
was 9.56 years, and their predicted life expectancy (had they had access to the 1995 stock 
of drugs) was 10.59 years.  In this sense, the 1975-1995 increase in the lagged stock of 
drugs made the life expectancy of people diagnosed with cancer in 1995 just over a year 
greater than the life expectancy of people diagnosed with cancer in 1975. 
 In a previous study (Lichtenberg (2005)), I estimated the effect of launches of 
new drugs for all diseases on the longevity of the entire populations of 52 countries 
(including the U.S.) during the period 1986-2000.  The methodology used in that study 
differed from the one used here: the dependent variable was a measure of the age 
distribution of deaths, rather than the hazard rate of people previously diagnosed.26  
Although the sample and methodology were quite different, the estimated contribution of 
                                                 
26 27% of the deaths occurring in that sample were caused by cancer. 
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pharmaceutical innovation to longevity increase was very similar to the one calculated 
above.  Before I estimated that the average annual increase in life expectancy of the entire 
population resulting from new chemical entity launches is .056 years, or 2.93 weeks.  
Now I estimate that the average annual increase in life expectancy of Americans 
diagnosed with cancer resulting from new chemical entity launches is .051 years, or 2.67 
weeks.   
 According to the National Cancer Institute, the lifetime risk of being diagnosed 
with cancer is about 40%.  This implies that the 1975-1995 increase in the lagged stock 
of cancer drugs increased the life expectancy of the entire U.S. population by 0.4 years (= 
40% * 1.03 years).   Between 1975 and 1995, U.S. life expectancy at birth increased by 
3.8 years, from 72.3 years to 76.1 years.27  Thus, new cancer drugs accounted for 10.7% 
of the overall increase in life expectancy at birth. 
How much did it cost to achieve this additional year of life per person diagnosed 
with cancer?  To determine this cost (c), I will estimate the average amount spent on 
cancer drugs by a cancer patient from time of diagnosis until death, using the following 
formula: 
c = 
total drug 
expenditure 
in 1995 × 
cancer drug expenditure 
  total drug expenditure 
÷ 1995 
cancer 
prevalence
× mean life 
expectancy at 
time of diagnosis 
 
According to the Center for Medicare and Medicaid Services, Americans spent $60.8 
billion on prescription drugs in 1995.28  We have two different estimates of the share of 
cancer drug expenditure in total drug expenditure.  According to the Census Bureau, 
“specific antineoplastic agents” accounted for 1.3% of the value of 1995 shipments of 
pharmaceutical preparations (except biologicals).  According to IMS Health, cytostatic 
drugs accounted for 3.6% of total U.S. drug sales in 2002.29  Hence total cancer drug 
expenditure during 1995 was presumably between $803 million (= 1.3% * $60.8 billion) 
and $2194 million (= 3.6% * $60.8 billion).   According to the NCI, cancer prevalence 
was 8.0 million in 1995.  Hence average 1995 expenditure on cancer drugs per cancer 
patient was in the range $100-$274.  As discussed above, estimated life expectancy of 
                                                 
27 Arias and Smith (2003), Table 11. 
28 http://cms.hhs.gov/statistics/nhe/historical/t2.asp 
29 http://open.imshealth.com/download/oct2002.pdf 
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people diagnosed with cancer in 1995 is about 10.6 years.  Hence, average 
(undiscounted) cancer drug expenditure per cancer patient from diagnosis till death is in 
the range $1064-$2907.  The cost per life-year gained is in the $1040-$2842 range.   
This is far below recent estimates of the value of a statistical life-year.  Murphy 
and Topel (2003) and Nordhaus (2003) estimate that this value is in the neighborhood of 
$150,000.  Moreover, since drug expenditures calculated above include expenditures on 
old as well as new drugs, this range represents an upper bound on the cost per life-year 
gained.  Data from the Medical Expenditure Panel Survey suggest that, in general, new 
drugs—drugs approved within the previous 15-20 years—account for about half of total 
drug expenditure.  If this applied to cancer drugs, we should divide the cost per life-year 
estimates by two.   However, given the rapid increase in the number of cancer drugs, new 
cancer drugs may account for more than half of total cancer drug expenditure.   
 We have examined the effect of new cancer drugs on the life expectancy, or 
number of remaining life-years, of cancer patients at time of diagnosis.  Ideally, we 
would like to measure the effect on the number of quality-adjusted life-years.  Health 
economists generally postulate a quality-of-life index (QOL) that ranges between 1 
(corresponding to perfect health) and 0 (corresponding to death).  The number of quality-
adjusted life-years (QALYs) is the number of years multiplied by the average value of the 
quality-of-life index during those years.  For example, 10 years lived at mean QOL=0.7 
equals 7 QALYs.  Unfortunately, SEER does not collect any data on the quality of life of 
cancer survivors, so calculating the impact of new cancer drugs on the number of QALYs 
is not feasible. 
 While new cancer drugs appear to have increased the longevity of cancer 
survivors by about a year, QOL in that additional year is likely to have been much less 
than 1.  However, it is also plausible that, in addition to delaying death, new cancer drugs 
increased the quality of life of people at a given number of years after diagnosis.  If this is 
the case, the increase in QALYS is not necessarily less than the increase in life 
expectancy.   
 This is illustrated by Figure 14.  Suppose that new cancer drugs shifted the time-
QOL profile from the curve labeled ‘1975’ to the curve labeled ‘1995’.  This shift reflects 
the estimated increase in life expectancy, from 9.56 years to 10.59 years.  The increase in 
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life-years is equal to the sum of areas A and B.  This is significantly larger than area A 
alone—the QOL-adjusted value of the additional 1.03 years.  But we hypothesize that 
new drugs also increased average QOL from year 0 to year 9.56.  The increase in QALYs 
during that period is measured by area C.  Clearly A < (A + B), but (A + C) is not 
necessarily smaller than (A + B).  Whether it is depends on the relative magnitudes of B 
and C: average QOL in the marginal years versus QOL improvement in the inframarginal 
years. 
 One might suppose that increasing the longevity of cancer patients will inevitably 
result in an increase in medical expenditure on them.  But Lubitz et al (2003) found that 
although elderly persons in better health had a longer life expectancy than those in poorer 
health, they had similar cumulative health care expenditures until death. 
 
V.  International differences in cancer survival rates 
 
In this section, I will investigate the effect of availability of new drugs on cancer 
survival rates in over 35 countries.  I will distinguish between 17 different types of cancer 
(breast cancer, colon cancer, leukemia, etc.).  The data will be drawn from three different 
sources: 
• The GLOBOCAN 2000 database.  This database provides data on incidence and 
survival, by country, by cancer site.30 It has been built up using the huge amount 
of data available in the Unit of Descriptive Epidemiology of the International 
Agency for Research on Cancer (IARC), part of the World Health Organization.  
Incidence data are available from cancer registries. (www-
dep.iarc.fr/globocan/globocan.html) 
• The Cancer Care Ontario (CCO) Formulary. This is a standardized reference and 
operational compilation of cancer drug monographs, chemotherapy regimens, and 
supportive care and symptom control regimens.  It provides data on drugs, by 
cancer site, and includes uses approved by the Therapeutic Products Programme 
of Health Canada as well as "other uses" that have been reported in the literature. 
(http://www.cancercare.on.ca/access_drugFormulary.htm) 
• IMS Health New Product Focus. This database monitors initial launches of new, 
branded and generic pharmaceuticals, enabling identification of manufacturer, 
date and country of launch, composition, indication, dosage, packaging and price 
at first launch for over 180,000 product launches worldwide since 1982.  
 
                                                 
30 The incidence and survival data are both age-adjusted.  Generally, the survival data refer to relative 
survival, which is the probability of not dying from the cancer concerned, excluding other causes of death. 
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These data enable estimation of the following model: 
 
SURVij = β ln(N_DRUGij) + αi + δj + εij     (2) 
 
where 
 
SURVij = the (1-year or 5-year) survival rate for cancer type i in country j 
N_DRUGij = the number of drugs for cancer type i available in country j 
αi  = a fixed effect for cancer type i 
δj = a fixed effect for country j 
εij = a disturbance 
 
I hypothesize that β > 0: the greater the number of drugs available to treat cancer type i in 
country j, the higher the survival rate.  Note that the model includes both fixed cancer-
type effects and fixed country effects.  This means that we are controlling for all 
determinants of cancer survival that are invariant across cancer types within a given 
country, and that are invariant across countries for a given cancer type.  For example, 
suppose that rich countries tend to have many drugs available and high cancer survival 
rates, controlling for the number of drugs available.  If we failed to control for country 
income, we would overstate the impact of drug availability per se.  Inclusion of country 
effects (δj‘s) controls for country income, as well as for other difficult-to-measure 
country attributes (e.g. the overall quality of cancer treatment) that may influence cancer 
survival rates and may be correlated with cancer drug availability.   
Due to inclusion of fixed cancer-type and country effects in the model, β 
represents the effect of relative drug availability within a country on relative survival 
rates within the country.  Suppose that, on average (across all countries), the survival rate 
of cancer type A is 25% higher than the survival rate of cancer type B, and the number of 
drugs for cancer type A is 35% higher than the number of drugs for cancer type B.  Then 
one would expect that if, in a particular country, the number of drugs for cancer type A is 
only 20% higher than the number of drugs for cancer type B, that the survival rate of 
cancer type A is less than 25% higher than the survival rate of cancer type B.  Indeed, 
estimation of the model requires that the relative availability of drugs for different cancer 
types varies across countries. 
The data allow me to test a hypothesis about the determinants, as well as the 
consequences, of relative drug availability.  The hypothesis is that the probability that 
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cancer drug d has been launched in country j depends on the incidence of cancer cases 
eligible for treatment by that drug in that country.  In other words, we hypothesize that β’ 
> 0 in the following model: 
 
LAUNCHEDdj = β’ f(N_CASESdj) + α’d + δ’j + ε’ij    (3) 
 
where 
 
LAUNCHEDdj = 1 if cancer drug d has been launched in country j 
= 0 if cancer drug d has not been launched in country j 
N_CASESdj = annual number of new cases eligible for treatment by drug d in 
country j 
α'd  = a fixed effect for cancer drug d 
δ'j = a fixed effect for country j 
ε'dj = a disturbance 
 
The annual number of new cases eligible for treatment by drug d in country j may be 
calculated as follows: 
 
N_CASESdj = ∑i (USEDdi × N_CASESij)     (4) 
 
where31 
 
USEDdi  = 1 if drug d is used to treat cancer type i 
= 0 if drug d is not used to treat cancer type i 
N_CASESij = the incidence (annual number of new cases) of cancer type i in country j 
 
Previous studies (e.g. Danzon, Wang, and Wang (2005), and Kyle (2005)) have examined 
the effect of potential market size on the probability and timing of drug launch.  But the 
market size variable used in those studies is simply the country’s population.  Our data on 
incidence by cancer type and country enable more precise measurement of market size.   
 I calculated probit estimates of eq. (3) using three different functional forms: log, 
linear, and quadratic.  Estimates of the N_CASES coefficients are shown in the following 
table.32 
                                                 
31 While some drugs are used to treat only one type of cancer, others are used to treat several types.  For 
example, amsacrine is only used to treat leukemia, but etoposide is used to treat ten types of cancer. 
32 The models were estimated using 1228 observations (33 ingredients * 38 countries – 24 missing values).  
The ratio of actual drug launches to potential drug launches was 63%. 
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  estimate std. err. chi-sq p-value 
Model 1     
log(N_CASES) 0.18 0.15 1.45 0.23 
      
Model 2     
N_CASES 0.01 0.00 3.81 0.05 
      
Model 3     
N_CASES 0.01 0.00 5.07 0.02 
N_CASES2 -0.00 0.00 2.68 0.10 
 
In model 1, the coefficient on log(N_CASES) is positive, as expected, but not statistically 
significant.  In model 2, the coefficient on N_CASES is positive and significant at the 5% 
level.  Model 3 suggests that the relationship between the probability of drug launch and 
N_CASES is concave, although the quadratic term is significant at only the 10% level.   
In general, this evidence supports the hypothesis that, ceteris paribus, the probability that 
a cancer drug has been launched in a country depends on the incidence of cancer cases 
eligible for treatment by that drug in that country.   
 Appendix Table 3 shows the cross-classification of cancer drugs by cancer site.  
There are 9 or more drugs for breast cancer, leukemia, and lung cancer, but only one drug 
for five types of cancer.  Appendix Table 4 shows cancer drugs by country.  Five 
countries (Canada, Finland, the U.S., Denmark, and the U.K.) had 30 or more cancer 
drugs launched; five countries (Saudi Arabia, Peru, Egypt, Venezuela) had 10 or fewer 
launched.  However, due to the presence of fixed effects in eq. (2), cross-country 
differences in the total number of drugs launched will have no effect on our estimates.  
Our estimates will depend only on the relative number of drugs launched for different 
types of cancer within a country.   
Data on the number of post-1982 NCEs by country and cancer site are shown in 
Table 5.  Ireland had 8 leukemia drugs and 5 lung cancer drugs, while Spain had 4 
leukemia drugs and 7 lung cancer drugs.  One might therefore expect the ratio of the 
leukemia survival rate to the lung cancer survival rate to be higher in Ireland than it is in 
Spain. 
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The following table shows summary data for all cancer sites but non-melanoma 
skin for the year 2002. 
Region Incidence 1-year surv. rate 5-year surv. rate 
World  10,862,496 63% 45% 
More developed region 5,016,114 75% 57% 
Less developed region 5,827,505 53% 35% 
 
Almost eleven million cancer cases were diagnosed worldwide in 2002.  Slightly more 
than half of these were in the less-developed region.  The 5-year survival rate is 62% 
higher in the more developed region than it is in the less-developed region. 
 I will now present estimates of a number of specifications of the survival model 
(eq. (2)).  I will present estimates of 12 (= 2 * 2 * 3) models: two survival durations (1-
year and 5-year), not controlling and controlling for cancer incidence, and three 
estimation methods: weighted least-squares (WLS) estimation of a model of the survival 
rate, WLS estimation of a model of the log-odds of survival,33 and estimation of a probit 
model of survival.  I estimate models that control for cancer incidence (by including 
ln(N_CASESij) as an additional regressor in eq. (2)), because higher incidence may be 
associated with greater survival for reasons other than greater drug availability.34  The 
WLS estimates are likely to substantially understate the statistical significance of our 
estimates.  These estimates assume that we have only about 577 observations (17 cancer 
sites * 38 countries).  But total cancer incidence in our sample is about 3.5 million cases.  
The probit estimates assume that we have 3.5 million observations.  The GLOBOCAN 
incidence and survival statistics may be based on samples rather than censuses, so the 
statistical significance of the probit estimates may be somewhat overstated.  The WLS 
and probit estimates are likely to provide lower and upper bounds of the true statistical 
significance of the estimates. 
 Estimates of the twelve survival models are shown in Table 6.  The top panel 
shows estimates of models of the one-year survival rate.  The estimates in all six columns 
indicate that an increase in the number of available drugs is associated with an increase in 
                                                 
33 The log-odds is defined as log (S / (1 – S)), where S denotes the survival rate. 
34 For example, the introduction of new imaging technology could result in higher measured incidence, 
earlier detection, and higher survival.  Controlling for incidence is likely to result in conservative estimates 
of the effect of drug availability on survival. 
 32
the one-year survival rate.  When ln(N_CASES) is included in the model (in columns 2, 
4, and 6), its coefficient is also positive and highly significant, indicating that an increase 
in relative incidence is associated with an increase in the relative survival rate (misery 
loves company?), but controlling for incidence results in only a small reduction in the 
coefficient on ln(N_DRUG).   
The bottom panel shows estimates of models of the five-year survival rate.  The 
ln(N_DRUG) coefficients in columns 1-4 are positive, but significant at only about the 
10% level when we control for ln(N_CASES).  However, as argued above, the WLS 
estimates are likely to substantially understate statistical significance.  The probit 
estimates are highly significant.  Therefore, I think it is safe to conclude that an increase 
in the number of available drugs is associated with an increase in the five-year as well as 
the one-year survival rate. 
One way to assess the magnitude of the effect of access to new cancer drugs on 
cancer survival is to calculate the implied effect of moving from a low value to a high 
value in the N_DRUG distribution.  Countries at about the 90th percentile of the 
N_DRUG distribution (Denmark and the U.K.) each had 30 drugs; countries at about the 
10th percentile of the N_DRUG distribution (Peru and Egypt) each had 9 drugs.  The 
estimates in column 2 imply that increasing the number of drugs from 9 to 30 would 
increase the 1-year survival rate by 3.0 percentage points (which is 4.6% of the mean 1-
year survival rate (66%)), and it would increase the 5-year survival rate by 2.2 percentage 
points (which is 4.3% of the mean 5-year survival rate (51%)).  This is only about 20% of 
the observed differential in 1-year survival rates, and 14% of the observed differential in 
5-year survival rates, between Denmark and the U.K. on the one hand and Peru and 
Egypt on the other hand.   
The analysis in previous sections indicated that variation in access to new drugs 
accounts for some of the variation over time in the relative survival rates of Americans 
with different types of cancer.  The analysis in this section indicated that variation in 
access to new drugs also accounts for some of the variation across countries in the 
relative survival rates of people with different types of cancer.  As I found in a previous 
study of all diseases (Lichtenberg (2005)), access to new drugs explains a larger fraction 
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of the time-series variation in longevity than it does of the international variation in 
longevity. 
 
VI.  Summary 
 
The age-adjusted U.S. mortality rate from all malignant cancers was essentially 
the same in 2000 as it was in 1969.  During the same period, the age-adjusted mortality 
rate from all other causes of death declined by 38%.  This suggests that the war on cancer 
has been a failure.  However, the relative stability of the cancer mortality rate is the result 
of two offsetting trends: an increase in the cancer incidence rate, and an increase in the 
relative survival rate.  The five-year relative survival rate from all malignant cancers 
increased from 50.0% in 1975-1979 to 62.7% in 1995.  This increase is not due to a 
favorable shift in the distribution of cancers.  
A variety of factors, including technological advances in diagnostic procedures 
that led to earlier detection and diagnosis, have probably contributed to this increase.  
This paper’s main objective has been to assess the contribution of pharmaceutical 
innovation to the increase in cancer survival rates.  Only about one third of the 
approximately 80 drugs currently used to treat cancer had been approved when the war 
on cancer was declared in 1971.  In other words, there has been a threefold increase in the 
size of the cancer drug armamentarium in the last three decades.   
The percentage increase in the survival rate varied considerably across cancer 
sites.  For example, the survival rate for colon cancer increased from 41% to 63%, while 
the survival rate from prostate cancer increased from 43% to 98%.  We hypothesized that 
these differential rates of progress were partly attributable to different rates of 
pharmaceutical innovation for different types of cancer.  The rate of increase of the stock 
of drugs also varied considerably across cancer sites in a given period, and also across 
periods for a given cancer site.  For example, between 1969 and 2002, there was a 4.4-
fold increase in the stock of drugs for breast cancer, and an 8-fold increase in the stock of 
drugs for prostate cancer.  Also, the stock of drugs for colon and rectum cancer remained 
constant from 1974 to 1980, but then doubled from 1980 to 1982.   
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We tested this hypothesis within a “differences in differences” framework, by 
estimating models of cancer mortality rates using longitudinal, annual, cancer-site-level 
data based on records of 2.1 million people diagnosed with cancer during the period 
1975-1995.  The explanatory variable of primary interest was the (lagged value of the) 
cumulative number of cancer drugs approved to treat that cancer type.  The following 
covariates were also included in the model: fixed cancer site effects, fixed year effects, 
incidence, stage distribution of diagnosed patients, mean age at diagnosis, percent of 
patients having surgery, and percent of patients having radiation.  Including these 
variables is likely to control for the effect of technological advances in diagnostic 
procedures.   
We argued that estimation of hazard-rate models was better suited to our purposes 
than estimation of survival-rate models, and we estimated separate hazard models for 
each of the years following diagnosis.  Overall, the estimates indicated that cancers for 
which the stock of drugs increased more rapidly tended to have larger reductions in 
hazard rates.  In hazard-rate models for the first eight years after diagnosis, the coefficient 
on the drug stock was negative three times as often as it was positive, and it was negative 
and significant twice as often as it was positive and significant.   Moreover, the 
coefficient on the drug stock was negative in the first three years (and significant in the 
first two), when the hazard rate is highest.  The estimates provided no support for the 
hypothesis that the introduction of a first-in-class drug increases cancer survival more 
than the introduction of subsequent drugs within the class. 
We used the estimates of the drug-stock coefficients to assess the effect of new 
drug introductions on the cancer survival distribution function and on life expectancy at 
time of diagnosis.  The estimates implied that, ceteris paribus—holding constant the 
cancer site- and stage-distribution, cancer incidence, mean age at diagnosis, and the 
probability of surgery and radiation—the 1975-1995 increase in the stock of drugs 
increased the 1-year crude cancer survival rate from 69.4% to 76.1%, the 5-year rate from 
45.5% to 51.3%, and the 10-year rate from 34.2% to 38.1%.  The increase in the stock of 
drugs accounted for about 50-60% of the increase in age-adjusted survival rates in the 
first 6 years after diagnosis. 
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Although the surgical treatment rate had a significant negative effect on hazard 
rates in a number of years, there was very little change in the overall surgical treatment 
rate during the sample period.  Hence, our estimates imply that changes in the surgical 
treatment rate (and in the radiation treatment rate) had a negligible impact on cancer 
survival rates during this period.   
We also estimated that the 1975-1995 increase in the lagged stock of drugs made 
the life expectancy of people diagnosed with cancer in 1995 just over a year greater than 
the life expectancy of people diagnosed with cancer in 1975.  This figure increased from 
about 9.6 to 10.6 years.  This is very similar to the estimate of the contribution of 
pharmaceutical innovation to longevity increase I obtained in an earlier study, although 
that study was based on a very different sample (all diseases in 52 countries) and 
methodology.  
Since the lifetime risk of being diagnosed with cancer is about 40%, the estimates 
imply that the 1975-1995 increase in the lagged stock of cancer drugs increased the life 
expectancy of the entire U.S. population by 0.4 years, and that new cancer drugs 
accounted for 10.7% of the overall increase in U.S. life expectancy at birth. 
The estimated cost to achieve the additional year of life per person diagnosed with 
cancer is well below recent estimates of the value of a statistical life-year.  The average 
amount spent on (new and old) cancer drugs by a cancer patient from time of diagnosis 
until death in 1995 was apparently below $3000.  Previous authors estimate that the value 
of a statistical U.S. life-year is in the neighborhood of $150,000. 
Ideally, we would have measured the effect of new cancer drugs on the number of 
quality-adjusted life-years (QALYs), but we were unable to do so due to lack of data.  
While new cancer drugs appear to have increased the longevity of cancer survivors by 
about a year, quality of life in that additional year is likely to have been much less than 1.  
However, if new cancer drugs increased the quality of life of people as well as delayed 
their death, the increase in QALYS is not necessarily less than the increase in life 
expectancy. 
I also investigated the effect of availability of new drugs on survival from 17 
types of cancer in over 35 countries.  The model included both fixed cancer-type effects 
and fixed country effects, which control for all determinants of cancer survival that are 
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invariant across cancer types within a given country, and that are invariant across 
countries for a given cancer type.  The estimates indicated that an increase in the number 
of available drugs is associated with an increase in both the one-year and the five-year 
survival rate.   
The analysis indicated that variation in access to new drugs accounts for: (1) some 
of the variation over time in the relative survival rates of Americans with different types 
of cancer, and (2) some of the variation across countries in the relative survival rates in 
2000 of people with different types of cancer.  Access to new drugs explains a larger 
fraction of the time-series variation in longevity than it does of the international variation 
in longevity.  The evidence also supported the hypothesis that, ceteris paribus, the 
probability that a cancer drug has been launched in a country depends on the incidence of 
cancer cases eligible for treatment by that drug in that country.   
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Survival rates, 1992-99 vs. 1950-54
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Table 1
5-year relative survival rates, by primary cancer site, 1950-54 and 1992-99 
Table 2
year of 
diagnos
is
number 
of people 
diagnose
d
mean 
age at 
diagno
sis
surgery 
treatment 
rate
radiation 
treatment 
rate stage0% stage1% stage2% stage4% stage8% stage9%
1973 55,382 61.4 55.1% 33.2% 7.1% 26.2% 17.9% 19.8% 4.7% 24.3%
1974 67,297 61.5 59.0% 31.2% 7.6% 29.3% 20.0% 20.7% 5.1% 17.4%
1975 73,608 61.4 63.4% 27.0% 8.5% 29.5% 19.2% 20.4% 5.5% 16.8%
1976 75,617 61.5 63.4% 26.4% 8.3% 29.4% 20.1% 20.6% 5.8% 15.8%
1977 76,591 61.8 63.3% 26.2% 7.9% 29.1% 21.0% 20.7% 6.2% 15.1%
1978 77,890 62.0 63.3% 26.5% 7.7% 29.6% 21.1% 21.2% 6.1% 14.4%
1979 80,126 62.3 63.4% 26.7% 7.5% 29.6% 21.3% 21.1% 6.6% 13.9%
1980 82,694 62.6 63.2% 26.3% 7.3% 29.4% 21.1% 21.3% 6.7% 14.0%
1981 85,364 62.7 63.6% 26.2% 7.3% 29.4% 21.4% 20.9% 6.8% 14.2%
1982 86,577 62.8 63.4% 26.3% 7.3% 29.0% 21.2% 21.3% 6.9% 14.5%
1983 89,724 63.0 63.7% 26.4% 7.6% 29.0% 23.0% 22.0% 6.6% 11.9%
1984 93,224 63.0 63.3% 26.4% 7.8% 28.9% 22.7% 22.0% 6.4% 12.3%
1985 97,498 62.9 64.5% 26.7% 8.5% 29.5% 22.0% 21.3% 6.5% 12.2%
1986 100,078 62.9 64.3% 26.1% 8.9% 29.9% 21.3% 20.4% 6.7% 12.8%
1987 105,871 63.2 64.4% 26.4% 9.2% 29.6% 20.7% 20.1% 7.6% 12.8%
1988 107,403 63.0 64.3% 26.2% 9.7% 29.7% 20.3% 20.1% 7.7% 12.4%
1989 110,185 63.0 63.7% 26.0% 9.9% 29.1% 19.8% 20.1% 8.2% 13.0%
1990 116,033 63.0 64.2% 26.3% 10.4% 28.7% 19.4% 19.3% 9.4% 12.8%
1991 123,115 63.2 63.5% 27.2% 10.4% 27.6% 18.2% 18.7% 11.7% 13.4%
1992 127,775 63.3 62.1% 27.9% 10.4% 27.5% 18.0% 17.8% 13.4% 12.9%
1993 125,917 63.1 61.6% 27.6% 10.7% 28.2% 18.2% 17.8% 12.4% 12.7%
1994 125,715 62.9 62.1% 27.4% 11.0% 29.3% 18.8% 17.7% 11.5% 11.7%
1995 127,069 62.7 62.6% 27.5% 11.8% 29.7% 18.5% 17.7% 11.3% 10.9%
1996 121,258 64.7 61.1% 30.0% 6.1% 32.1% 19.9% 18.8% 12.2% 11.0%
1997 125,352 64.8 61.3% 30.5% 6.4% 31.9% 19.9% 18.7% 12.5% 10.6%
1998 128,279 64.9 62.6% 31.7% 7.0% 32.2% 20.3% 18.3% 12.3% 9.8%
1999 129,930 64.8 62.8% 31.3% 7.2% 31.9% 20.4% 17.9% 13.4% 9.2%
2000 129,053 64.5 63.1% 30.9% 7.4% 32.3% 20.5% 18.1% 13.8% 7.9%
Table 2
Summary statistics from SEER Public Use File
Page 1
line Years after diagnosis Regressor Estimate Std. Error t Value Pr > |t|
1 1 ln(DRUG_STOCKi,t-3) -0.167 0.044 -3.78 0.0002
2 1 ln(Ni,t-k) -0.328 0.048 -6.88 <.0001
3 1 AGE_MEANi,t-k 0.075 0.006 13.35 <.0001
4 1 SURGERY%i,t-k -1.494 0.213 -7.02 <.0001
5 1 RADIATION%i,t-k 0.071 0.104 0.69 0.4921
6 1 STAGE0%i,t-k -1.381 0.389 -3.55 0.0004
7 1 STAGE1%i,t-k -2.820 0.199 -14.16 <.0001
8 1 STAGE2%i,t-k -1.935 0.266 -7.27 <.0001
9 1 STAGE4%i,t-k 2.855 0.236 12.11 <.0001
10 1 STAGE8%i,t-k -1.658 0.419 -3.96 <.0001
11
12 2 ln(DRUG_STOCKi,t-3) -0.156 0.049 -3.16 0.0016
13 2 ln(Ni,t-k) -0.249 0.055 -4.50 <.0001
14 2 AGE_MEANi,t-k 0.057 0.006 8.89 <.0001
15 2 SURGERY%i,t-k -1.145 0.241 -4.75 <.0001
16 2 RADIATION%i,t-k 0.410 0.104 3.95 <.0001
17 2 STAGE0%i,t-k -1.221 0.412 -2.96 0.0032
18 2 STAGE1%i,t-k -2.740 0.215 -12.75 <.0001
19 2 STAGE2%i,t-k -1.362 0.274 -4.97 <.0001
20 2 STAGE4%i,t-k 2.562 0.253 10.14 <.0001
21 2 STAGE8%i,t-k -1.350 0.499 -2.70 0.0071
22
23 3 ln(DRUG_STOCKi,t-3) -0.129 0.074 -1.73 0.084
24 3 ln(Ni,t-k) -0.391 0.073 -5.36 <.0001
25 3 AGE_MEANi,t-k 0.040 0.009 4.65 <.0001
26 3 SURGERY%i,t-k -1.092 0.321 -3.40 0.0007
27 3 RADIATION%i,t-k 0.160 0.132 1.21 0.2257
28 3 STAGE0%i,t-k -3.170 0.515 -6.15 <.0001
29 3 STAGE1%i,t-k -2.517 0.267 -9.41 <.0001
30 3 STAGE2%i,t-k -2.215 0.337 -6.56 <.0001
31 3 STAGE4%i,t-k 2.436 0.312 7.80 <.0001
32 3 STAGE8%i,t-k -2.581 0.704 -3.67 0.0003
33
34 4 ln(DRUG_STOCKi,t-3) 0.484 0.132 3.66 0.0003
35 4 ln(Ni,t-k) -0.276 0.128 -2.15 0.032
36 4 AGE_MEANi,t-k 0.034 0.015 2.30 0.0217
37 4 SURGERY%i,t-k 0.408 0.572 0.71 0.4763
38 4 RADIATION%i,t-k 0.678 0.237 2.86 0.0044
39 4 STAGE0%i,t-k -1.247 0.906 -1.38 0.1693
40 4 STAGE1%i,t-k -4.328 0.454 -9.53 <.0001
41 4 STAGE2%i,t-k -1.336 0.584 -2.29 0.0227
42 4 STAGE4%i,t-k 4.043 0.532 7.60 <.0001
43 4 STAGE8%i,t-k 1.222 1.300 0.94 0.3477
Table 3
Estimates of eq. (1)
line Years after diagnosis Regressor Estimate Std. Error t Value Pr > |t|
44 5 ln(DRUG_STOCKi,t-3) -0.323 0.098 -3.30 0.001
45 5 ln(Ni,t-k) -0.010 0.098 -0.10 0.9221
46 5 AGE_MEANi,t-k 0.013 0.011 1.23 0.2174
47 5 SURGERY%i,t-k 0.454 0.430 1.06 0.2913
48 5 RADIATION%i,t-k 0.090 0.173 0.52 0.6026
49 5 STAGE0%i,t-k 1.256 0.679 1.85 0.0648
50 5 STAGE1%i,t-k -1.213 0.347 -3.50 0.0005
51 5 STAGE2%i,t-k 1.302 0.437 2.98 0.003
52 5 STAGE4%i,t-k -0.011 0.419 -0.03 0.9791
53 5 STAGE8%i,t-k -1.867 1.030 -1.81 0.0706
54
55 6 ln(DRUG_STOCKi,t-3) -0.327 0.120 -2.73 0.0066
56 6 ln(Ni,t-k) 0.024 0.118 0.20 0.8377
57 6 AGE_MEANi,t-k -0.006 0.013 -0.43 0.6664
58 6 SURGERY%i,t-k 0.573 0.514 1.11 0.2654
59 6 RADIATION%i,t-k -0.360 0.211 -1.71 0.0882
60 6 STAGE0%i,t-k -4.545 0.843 -5.39 <.0001
61 6 STAGE1%i,t-k -1.840 0.400 -4.60 <.0001
62 6 STAGE2%i,t-k -1.877 0.549 -3.42 0.0007
63 6 STAGE4%i,t-k 1.454 0.489 2.97 0.0031
64 6 STAGE8%i,t-k -3.811 1.338 -2.85 0.0046
65
66 7 ln(DRUG_STOCKi,t-3) 0.385 0.134 2.88 0.0042
67 7 ln(Ni,t-k) -0.325 0.139 -2.33 0.0203
68 7 AGE_MEANi,t-k 0.078 0.015 5.09 <.0001
69 7 SURGERY%i,t-k -0.628 0.590 -1.06 0.2879
70 7 RADIATION%i,t-k 0.786 0.247 3.18 0.0015
71 7 STAGE0%i,t-k 2.080 0.971 2.14 0.0327
72 7 STAGE1%i,t-k -0.295 0.446 -0.66 0.509
73 7 STAGE2%i,t-k 2.131 0.576 3.70 0.0002
74 7 STAGE4%i,t-k -0.708 0.546 -1.30 0.1951
75 7 STAGE8%i,t-k -2.602 2.023 -1.29 0.199
76
77 8 ln(DRUG_STOCKi,t-3) -0.179 0.193 -0.93 0.3551
78 8 ln(Ni,t-k) -0.456 0.172 -2.66 0.0082
79 8 AGE_MEANi,t-k 0.038 0.020 1.90 0.0575
80 8 SURGERY%i,t-k -1.613 0.707 -2.28 0.0229
81 8 RADIATION%i,t-k -0.709 0.319 -2.22 0.0269
82 8 STAGE0%i,t-k 2.593 1.198 2.16 0.031
83 8 STAGE1%i,t-k -0.441 0.509 -0.87 0.386
84 8 STAGE2%i,t-k 1.069 0.701 1.52 0.128
85 8 STAGE4%i,t-k -0.339 0.629 -0.54 0.5908
86 8 STAGE8%i,t-k -2.679 2.994 -0.89 0.3713
Table 3 (continued)
Estimates of eq. (1)
Column 1 2 3 4 5 6 7 8 9
Year βk Error t Value Pr > |t| HAZ_ACT HAZ_PRE SURV_ACT SURV_PRE 1995 SURV_ACT
0 100.0% 100.0% 100.0%
1 -0.167 0.044 -3.78 2E-04 30.6% 23.9% 69.4% 76.1% 76.7%
2 -0.156 0.049 -3.16 0.002 14.7% 11.7% 59.2% 67.2% 67.9%
3 -0.129 0.074 -1.73 0.084 10.1% 8.4% 53.2% 61.5% 62.6%
4 0.484 0.132 3.66 3E-04 8.0% 13.1% 49.0% 53.5% 58.6%
5 -0.323 0.098 -3.30 0.001 7.1% 4.1% 45.5% 51.3% 55.2%
6 -0.327 0.120 -2.73 0.007 6.5% 3.7% 42.5% 49.4% 51.8%
7 0.385 0.134 2.88 0.004 5.6% 8.4% 40.1% 45.2%
8 -0.179 0.193 -0.93 0.355 5.3% 4.0% 38.0% 43.4%
9 0.247 0.191 1.29 0.197 5.0% 6.6% 36.1% 40.6%
10 0.098 0.187 0.53 0.599 5.3% 5.9% 34.2% 38.1%
11 -0.709 0.240 -2.96 0.003 4.7% 0.3% 32.6% 38.0%
12 -0.467 0.247 -1.89 0.059 4.7% 1.8% 31.1% 37.3%
13 0.436 0.240 1.82 0.07 4.5% 7.1% 29.7% 34.7%
14 0.084 0.236 0.36 0.723 4.4% 4.9% 28.4% 33.0%
15 -0.088 0.318 -0.28 0.782 4.6% 4.1% 27.1% 31.6%
16 -0.567 0.358 -1.58 0.115 4.6% 1.2% 25.8% 31.2%
17 0.095 0.320 0.30 0.766 4.5% 5.0% 24.7% 29.7%
18 0.984 0.327 3.01 0.003 4.3% 9.9% 23.6% 26.7%
19 0.943 0.483 1.95 0.053 4.4% 9.9% 22.5% 24.1%
20 1.114 0.517 2.16 0.033 4.5% 11.2% 21.5% 21.4%
21 -0.344 0.534 -0.64 0.522 5.0% 2.7% 20.4% 20.8%
22 0.112 0.587 0.19 0.849 4.6% 5.3% 19.5% 19.7%
23 -1.306 1.076 -1.21 0.23 5.4% -3.8% 18.4% 20.5%
24 1.290 0.613 2.10 0.046 5.3% 14.3%
Table 4
Actual vs. predicted hazard and survival rates
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Mean, all countries 3.0 4.5 2.2 9.6 0.9 1.6 1.4 5.8 6.8 1.0 0.3 3.7 0.8 3.7 0.8 4.6 3.2 0.9
CANADA 4.2 6 3 14 1 3 2 8 9 1 1 5 1 5 2 6 4 1
FINLAND 4.2 6 3 14 1 3 2 9 9 1 1 5 1 5 1 6 4 1
DENMARK 4.1 6 3 13 1 2 2 9 9 1 1 5 1 5 1 6 4 1
USA 4.1 6 3 13 1 2 2 8 9 1 1 5 1 5 2 6 4 1
ITALY 3.9 6 3 13 1 3 2 7 9 1 0 5 1 5 1 5 4 1
SWITZERLAND 3.9 6 3 12 1 3 2 9 8 1 0 5 1 5 1 5 4 1
NETHERLANDS 3.9 6 2 10 1 2 2 9 8 1 1 5 1 5 2 6 4 1
ARGENTINA 3.8 6 3 11 1 2 2 8 9 1 0 4 1 5 1 6 4 1
SWEDEN 3.8 6 3 11 1 1 1 9 8 1 1 5 1 5 1 6 4 1
MEXICO 3.8 6 3 11 1 2 2 7 9 1 0 5 1 4 1 6 4 1
UK 3.8 5 3 13 1 3 2 8 8 1 1 4 0 5 1 5 3 1
AUSTRALIA 3.7 6 3 10 1 3 1 8 8 1 0 5 1 5 1 5 4 1
BRAZIL 3.7 6 2 13 1 2 2 5 9 1 0 4 1 5 1 6 4 1
THAILAND 3.7 6 3 12 1 1 1 8 9 1 0 5 1 5 1 4 4 1
PHILIPPINES 3.6 6 2 12 1 3 1 5 9 1 0 5 1 4 1 5 4 1
AUSTRIA 3.5 4 3 13 1 2 2 6 7 1 1 4 1 4 1 4 4 1
BELGIUM 3.5 5 3 13 1 1 1 6 8 1 0 5 1 4 0 5 4 1
JAPAN 3.5 6 2 9 1 1 1 7 9 1 0 5 1 5 1 5 4 1
GREECE 3.4 6 2 12 0 2 2 6 8 1 0 4 1 4 1 5 3 0
IRELAND 3.2 3 1 12 1 3 2 8 5 1 1 5 1 3 0 4 3 1
TURKEY 3.2 5 2 9 1 1 2 6 8 1 0 3 1 5 1 5 3 1
SPAIN 3.1 5 3 10 1 1 1 4 7 1 0 5 1 3 1 5 4 1
CHILE 3.1 5 3 8 1 1 2 5 6 1 0 5 1 4 0 5 4 1
FRANCE 3.0 4 1 11 1 1 1 5 6 1 1 4 1 4 0 6 3 1
PAKISTAN 2.9 6 2 9 1 0 1 4 8 1 0 4 1 4 1 3 4 1
NEW ZEALAND 2.9 4 3 8 1 2 1 6 6 1 1 3 1 3 1 4 3 1
COLOMBIA 2.8 4 2 8 1 3 1 5 5 1 0 4 1 2 1 5 4 1
INDONESIA 2.5 4 2 7 1 2 1 4 6 1 0 2 1 3 1 3 3 1
SOUTH AFRICA 2.5 3 2 8 1 2 1 4 6 1 0 3 1 3 1 3 2 1
ISRAEL 2.4 2 1 9 1 1 1 6 4 1 0 3 1 3 0 5 2 1
EGYPT 2.3 4 1 6 1 0 1 4 5 1 0 4 1 3 0 4 3 1
PERU 2.0 3 2 4 1 0 1 3 6 1 0 2 1 2 1 3 3 1
MALAYSIA 1.8 2 3 6 1 0 1 3 4 1 0 1 0 3 0 3 2 1
ECUADOR 1.5 3 1 4 0 0 1 2 4 1 0 1 1 2 1 3 2 0
SAUDI ARABIA 1.5 4 1 4 0 0 1 2 5 1 0 1 0 2 1 2 2 0
SINGAPORE 1.4 1 0 7 0 2 1 4 3 1 1 1 0 1 0 2 0 0
PORTUGAL 1.1 0 1 3 1 0 1 2 1 1 0 1 0 1 0 5 1 1
Table 5
Number of post-1982 NCEs by country and cancer site
Column 1 2 3 4 5 6
Estimation method WLS WLS WLS WLS Probit Probit
Dependent variable
survival 
rate
survival 
rate log odds log odds survival rate survival rate
N 577 577 577 577 3,538,321 3,538,321
ln(N_DRUG)
estimate 0.029 0.025 0.258 0.238 0.110 0.098
std. err. 0.012 0.011 0.076 0.074 0.004 0.004
t-stat 2.45 2.23 3.39 3.21
chi-sq 880.87 701.41
p-value 0.0146 0.0264 0.0008 0.0014 <.0001 <.0001
N
ln(N_CASES)
estimate 0.043 0.191 0.119
std. err. 0.005 0.033 0.002
t-stat 8.64 5.83
chi-sq 5314.23
p-value <.0001 <.0001 <.0001
ln(N_DRUG)
estimate 0.024 0.018 0.111 0.089 0.070 0.055
std. err. 0.013 0.011 0.057 0.053 0.004 0.004
t-stat 1.87 1.58 1.96 1.69
chi-sq 386.8 235.47
p-value 0.0624 0.1149 0.051 0.091 <.0001 <.0001
N
ln(N_CASES)
estimate 0.055 0.221 0.145
std. err. 0.005 0.023 0.002
t-stat 10.71 9.49
chi-sq 8336.8
p-value <.0001 <.0001 <.0001
Note: all equations include country fixed effects and cancer-site fixed effects.
WLS estimates are weighted by N_CASESij
1-year survival
5-year survival
Table 6
Estimates of survival models
FDA 
approval 
year drug FDA approval year drug
before 1938 ASPARAGINASE 1987 MITOXANTRONE
before 1938 BCG 1988 IFOSFAMIDE
1949 MECHLORETHAMINE 1988 MESNA
1953 METHOTREXATE 1988 OCTREOTIDE
1954 BUSULFAN 1989 CARBOPLATIN
1955 DIETHYLSTILBESTROL 1989 FLUTAMIDE
1955 FLUDROCORTISONE 1989 GOSERELIN
1958 FLUOXYMESTERONE 1990 IDARUBICIN
1959 CYCLOPHOSPHAMIDE 1990 LEVAMISOLE
1959 THIOTEPA 1991 FLUDARABINE
1961 VINBLASTINE 1991 PAMIDRONATE
1962 FLUOROURACIL 1991 PENTOSTATIN
1962 MEDROXYPROGESTERONE 1992 PACLITAXEL
1963 MERCAPTOPURINE 1992 TENIPOSIDE
1964 DACTINOMYCIN 1993 CLADRIBINE
1966 THIOGUANINE 1994 TAMOXIFEN
1967 HYDROXYUREA 1994 VINORELBINE
1969 CHLORAMBUCIL 1995 ANASTROZOLE
1969 CYTARABINE 1995 BICALUTAMIDE
1969 PROCARBAZINE 1995 DAUNORUBICIN
1970 MELPHALAN 1995 PORFIMER
1970 MITOTANE 1996 DOCETAXEL
1970 PLICAMYCIN 1996 GEMCITABINE
1971 TRETINOIN 1996 IRINOTECAN
1973 BLEOMYCIN 1996 NILUTAMIDE
1974 DOXORUBICIN 1996 TOPOTECAN
1974 LEUCOVORIN 1997 LETROZOLE
1975 DACARBAZINE 1997 RITUXIMAB
1976 LOMUSTINE 1998 CAPECITABINE
1976 MEGESTROL 1998 TRASTUZUMAB
1977 CARMUSTINE 1999 EPIRUBICIN
1978 CISPLATIN 1999 EXEMESTANE
1980 AMINOGLUTETHIMIDE 1999 TEMOZOLOMIDE
1981 ESTRAMUSTINE 2002 OXALIPLATIN
1981 MITOMYCIN not FDA approved AMSACRINE
1982 STREPTOZOCIN not FDA approved BUSERELIN
1983 ETOPOSIDE not FDA approved CLODRONATE
1984 VINCRISTINE not FDA approved CYPROTERONE
1985 LEUPROLIDE not FDA approved RALTITREXED
1986 INTERFERON ALFA not FDA approved VINDESINE
Appendix Table 1
Drugs listed in British Columbia Cancer Drug Manual, by year of FDA approval
Drug class Number of drugs
ALKYLATING AGENT 12
ANTITUMOUR ANTIBIOTIC 9
ANTIMETABOLITE 8
ENDOCRINE HORMONE 8
ENDOCRINE ANTIHORMONE 5
MITOTIC INHIBITOR 4
ALKYLATING AGENT, CYTOTOXIC 3
ANTIMETABOLITE, CYTOTOXIC 3
AROMATASE INHIBITOR, NONCYTOTOXIC 3
BIOLOGICAL RESPONSE MODIFIER 3
BONE METABOLISM REGULATOR, NONCYTOTOXIC 2
MITOTIC INHIBITOR, CYTOTOXIC 2
MONOCLONAL ANTIBODY, NONCYTOTOXIC 2
TOPOISOMERASE I INHIBITOR, CYTOTOXIC 2
ANTITUMOUR ANTIBIOTIC (EMERGENCY RELEASE) 1
DIFFERENTIATION INDUCING AGENT, NONCYTOTOXIC 1
ENDOCRINE ANTIHORMONE, NONCYTOTOXIC 1
ENDOCRINE HORMONE, NONCYTOTOXIC 1
MISCELLANEOUS 10
Appendix Table 2
Distribution of drugs listed in British Columbia Cancer Drug Manual, by drug class
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All 73 6 3 14 1 3 2 9 9 1 1 5 1 5 2 6 4 1
etoposide 10 x x x x x x x x x x
methotrexate 7 x x x x x x x
mitoxantrone 7 x x x x x x x
carboplatin 5 x x x x x
epirubicin 5 x x x x x
paclitaxel 4 x x x x
gemcitabine 3 x x x
interferon 3 x x x
capecitabine 2 x x
docetaxel 2 x x
pamidronate 2 x x
vinorelbine 2 x x
aldesleukin 1 x
amsacrine 1 x
anastrozole 1 x
bicalutamide 1 x
cladribine 1 x
clodronate 1 x
exemestane 1 x
fludarabine 1 x
flutamide 1 x
goserelin 1 x
idarubicin 1 x
imatinib 1 x
irinotecan 1 x
letrozole 1 x
nilutamide 1 x
raltitrexed 1 x
rituximab 1 x
streptozocin 1 x
temozolomide 1 x
topotecan 1 x
trastuzumab 1 x
x denotes that the drug is used to treat cancer at that site
Cancer site
Appendix Table 3
Cancer drugs by cancer site
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Grand Total 816 27 25 27 22 24 32 12 17 20 30 11 9 32 19 27 14 14 24 17 28 21 12
interferon 40 x x x x x x x x x x x x x x x x x x x x x x
flutamide 37 x x x x x x x x x x x x x x x x x x x x
goserelin 36 x x x x x x x x x x x x x x x x x x x x x
etoposide 35 x x x x x x x x x x x x x x x x x x x x
anastrozole 34 x x x x x x x x x x x x x x x x x x
bicalutamide 33 x x x x x x x x x x x x x x x x x x x
methotrexate 33 x x x x x x x x x x x x x x x x x x x x
carboplatin 32 x x x x x x x x x x x x x x x x x x
letrozole 31 x x x x x x x x x x x x x x x x x x
paclitaxel 31 x x x x x x x x x x x x x x x x x
epirubicin 29 x x x x x x x x x x x x x x x x x x
idarubicin 29 x x x x x x x x x x x x x x x x x
docetaxel 28 x x x x x x x x x x x x x x x x
gemcitabine 27 x x x x x x x x x x x x
mitoxantrone 27 x x x x x x x x x x x x x x x x
clodronate 26 x x x x x x x x x x x x x x x x x
vinorelbine 25 x x x x x x x x x x x x
irinotecan 24 x x x x x x x x x x x x x
rituximab 24 x x x x x x x x x x x x
exemestane 22 x x x x x x x x x x x x x x
topotecan 22 x x x x x x x x x x x x x x
capecitabine 21 x x x x x x x x x x x x x
fludarabine 21 x x x x x x x x x x x x
temozolomide 21 x x x x x x x x x x x x
cladribine 19 x x x x x x x x x x x
trastuzumab 19 x x x x x x x x x x x
nilutamide 17 x x x x x x x x x x x
aldesleukin 16 x x x x x x x x x x
raltitrexed 16 x x x x x x x x x x
imatinib 15 x x x x x x x
pamidronate 12 x x x x x x
amsacrine 10 x x x x x
streptozocin 4 x x
x denotes that the drug has been launched in the country
Appendix Table 4
Cancer drugs by country
ingredient
Grand Total
interferon
flutamide
goserelin
etoposide
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bicalutamide
methotrexate
carboplatin
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paclitaxel
epirubicin
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clodronate
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irinotecan
rituximab
exemestane
topotecan
capecitabine
fludarabine
temozolomide
cladribine
trastuzumab
nilutamide
aldesleukin
raltitrexed
imatinib
pamidronate
amsacrine
streptozocin
x denotes that the drug has been launched in the country
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x enotes that the drug has been la ched in the country
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Cancer drugs by country
